Paracrine recruitment and activation of fibroblasts by c-Myc expressing breast epithelial cells through the IGFs/IGF-1R axis.


Journal

International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124

Informations de publication

Date de publication:
15 11 2019
Historique:
received: 30 07 2018
revised: 26 06 2019
accepted: 30 07 2019
pubmed: 6 8 2019
medline: 18 2 2020
entrez: 6 8 2019
Statut: ppublish

Résumé

Fibroblasts are among the most abundant stromal cells in the tumor microenvironment (TME), progressively differentiating into activated, motile, myofibroblast-like, protumorigenic cells referred to as Cancer-Associated Fibroblasts (CAFs). To investigate the mechanisms by which epithelial cells direct this transition, the early stages of tumorigenesis were exemplified by indirect cocultures of WI-38 or human primary breast cancer fibroblasts with human mammary epithelial cells expressing an inducible c-Myc oncogene (MCF10A-MycER). After c-Myc activation, the conditioned medium (CM) of MCF10A-MycER cells significantly enhanced fibroblast activation and mobilization. As this was accompanied by decreased insulin-like growth factor binding protein-6 (IGFBP-6) and increased insulin-like growth factor-1 and IGF-II (IGF-I, IGF-II) in the CM, IGFs were investigated as key chemotactic factors. Silencing IGFBP-6 or IGF-I or IGF-II expression in epithelial cells or blocking Insulin-like growth factor 1 receptor (IGF-1R) activity on fibroblasts significantly altered fibroblast mobilization. Exposure of WI-38 fibroblasts to CM from induced MCF10A-MycER cells or to IGF-II upregulated FAK phosphorylation on Tyr

Identifiants

pubmed: 31381136
doi: 10.1002/ijc.32613
doi:

Substances chimiques

Culture Media, Conditioned 0
IGF1 protein, human 0
IGF1R protein, human 0
IGF2 protein, human 0
Insulin-Like Growth Factor Binding Protein 6 0
MYC protein, human 0
Proto-Oncogene Proteins c-myc 0
RNA, Small Interfering 0
Insulin-Like Growth Factor I 67763-96-6
Insulin-Like Growth Factor II 67763-97-7
Receptor, IGF Type 1 EC 2.7.10.1
Podophyllotoxin L36H50F353

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2827-2839

Informations de copyright

© 2019 UICC.

Références

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
Friedl P, Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011;147:992-1009.
Chen WJ, Ho CC, Chang YL, et al. Cancer-associated fibroblasts regulate the plasticity of lung cancer stemness via paracrine signalling. Nat Commun 2014;5:3472.
Kojima Y, Acar A, Eaton EN, et al. Autocrine TGF- and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA 2010;107:20009-14.
Kuzet SE, Gaggioli C. Fibroblast activation in cancer: when seed fertilizes soil. Cell Tissue Res 2016;365:607-19.
Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012;21:309-22.
Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer 2016;16:582-98.
Unger C, Kramer N, Unterleuthner D, et al. Stromal-derived IGF2 promotes colon cancer progression via paracrine and autocrine mechanisms. Oncogene 2017;36:5341-55.
Busch S, Acar A, Magnusson Y, et al. TGF-beta receptor type-2 expression in cancer-associated fibroblasts regulates breast cancer cell growth and survival and is a prognostic marker in pre-menopausal breast cancer. Oncogene 2015;34:27-38.
Augsten M. Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front Oncol 2014;4:62.
Albrengues J, Bertero T, Grasset E, et al. Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts. Nat Commun 2015;6:10204.
Magnussen S, Hadler-Olsen E, Latysheva N, et al. Tumour microenvironments induce expression of Urokinase plasminogen activator receptor (uPAR) and concomitant activation of gelatinolytic enzymes. PLoS One 2014;9:e105929.
Carriero MV, Stoppelli MP. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling. Curr Pharm Des 2011;17:1944-61.
Nielsen BS, Rank F, Illemann M, et al. Stromal cells associated with early invasive foci in human mammary ductal carcinoma in situ coexpress urokinase and urokinase receptor. Int J Cancer 2007;120:2086-95.
Xu WW, Li B, Guan XY, et al. Cancer cell-secreted IGF2 instigates fibroblasts and bone marrow-derived vascular progenitor cells to promote cancer progression. Nat Commun 2017;8:14399.
Livingstone C. IGF2 and cancer. Endocr Relat Cancer 2013;20:R321-39.
Bach LA, Fu P, Yang Z. Insulin-like growth factor-binding protein-6 and cancer. Clin Sci 2013;124:215-29.
Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012;12:159-69.
Kaaks R, Johnson T, Tikk K, et al. Insulin-like growth factor I and risk of breast cancer by age and hormone receptor status-a prospective study within the EPIC cohort. Int J Cancer 2014;134:2683-90.
Baxter RC. IGF binding proteins in cancer: mechanistic and clinical insights. Nat Rev Cancer 2014;14:329-41.
Zheng D, Kurenova E, Ucar D, et al. Targeting of the protein interaction site between FAK and IGF-1R. Biochem Biophys Res Commun 2009;388:301-5.
Sulzmaier FJ, Jean C, Schlaepfer DD. FAK in cancer: mechanistic findings and clinical applications. Nat Rev Cancer 2014;14:598-610.
Gabay M, Li Y, Felsher DW. MYC activation is a hallmark of cancer initiation and maintenance. Cold Spring Harb Perspect Med 2014;4:a014241.
Pocsfalvi G, Votta G, De Vincenzo A, et al. Analysis of secretome changes uncovers an autocrine/paracrine component in the modulation of cell proliferation and motility by c-Myc. J Proteome Res 2011;10:5326-37.
Kalkat M, De Melo J, Hickman KA, et al. MYC deregulation in primary human cancers. Genes (Basel) 2017;8:E151.
Alfano D, Votta G, Schulze A, et al. Modulation of cellular migration and survival by c-Myc through the downregulation of urokinase (uPA) and uPA receptor. Mol Cell Biol 2010;30:1838-51.
Soule HD, Maloney TM, Wolman SR, et al. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 1990;50:6075-86.
Gao M-Q, Kim BG, Kang S, et al. Stromal fibroblasts from the interface zone of human breast carcinomas induce an epithelial-mesenchymal transition-like state in breast cancer cells in vitro. J Cell Sci 2010;123:3507-14.
Vocca I, Franco P, Alfano D, et al. Inhibition of migration and invasion of carcinoma cells by urokinase-derived antagonists of alphavbeta5 integrin activation. Int J Cancer 2009;124:316-25.
Schmittgen T, Livak K. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101-8.
Franco P, Carotenuto A, Marcozzi C, et al. Opposite modulation of cell migration by distinct subregions of Urokinase connecting peptide. ChemBioChem 2013;14:882-9.
Timpson P, Mcghee EJ, Erami Z, et al. Organotypic collagen I assay: a malleable platform to assess cell behaviour in a 3-dimensional context. J Vis Exp 2011;56:3089.
Menu E, Jernberg-Wiklund H, Stromberg T, et al. Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood 2006;107:655-60.
Taliaferro-Smith L, Oberlick E, Liu T, et al. FAK activation is required for IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast cancer cells. Oncotarget 2015;6:4757-72.
Calvo F, Ege N, Grande-Garcia A, et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol 2013;15:637-46.
Miles FL, Sikes RA. Insidious changes in stromal matrix fuel cancer progression. Mol Cancer Res 2014;12:297-312.
Carriero MV, Franco P, Votta G, et al. Regulation of cell migration and invasion by specific modules of uPA: mechanistic insights and specific inhibitors. Curr Drug Targets 2011;12:1761-71.
Shan T, Lu H, Ji H, et al. Loss of stromal caveolin-1 expression: a novel tumor microenvironment biomarker that can predict poor clinical outcomes for pancreatic cancer. PLoS One 2014;9:e97239.
Al-Rakan MA, Colak D, Hendrayani SF, et al. Breast stromal fibroblasts from histologically normal surgical margins are pro-carcinogenic. J Pathol 2013;231:457-65.
Surowiak P, Murawa D, Materna V, et al. Occurence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor. Anticancer Res 2007;27:2917-24.
Christopoulos PF, Msaouel P, Koutsilieris M. The role of the insulin-like growth factor-1 system in breast cancer. Mol Cancer 2015;14:43.
Rajski M, Zanetti-Dällenbach R, Vogel B, et al. IGF-I induced genes in stromal fibroblasts predict the clinical outcome of breast and lung cancer patients. BMC Med 2010;8:1.
Gebeshuber CA, Martinez J. MiR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling. Oncogene 2013;32:3306-10.
Chen Q, Qin S, Liu Y, et al. IGFBP6 is a novel nasopharyngeal carcinoma prognostic biomarker. Oncotarget 2016;7:68140-50.
Charras G, Sahai E. Physical influences of the extracellular environment on cell migration. Nat Rev Mol Cell Biol 2014;15:813-24.
Gaggioli C, Hooper S, Hidalgo-Carcedo C, et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol 2007;9:1392-400.
McMullin R, Wittner B, Yang C, et al. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity. Breast Cancer Res 2014;16:R25.
Mezawa Y, Orimo A. The roles of tumor- and metastasis-promoting carcinoma-associated fibroblasts in human carcinomas. Cell Tissue Res 2016;365:675-89.
Iams WT, Lovly CM. Molecular pathways: clinical applications and future direction of insulin-like growth Factor-1 receptor pathway blockade. Clin Cancer Res 2015;21:4270-7.

Auteurs

Anna De Vincenzo (A)

Institute of Genetics and Biophysics "Adriano Buzzati Traverso", National Research Council, Naples, Italy.

Stefania Belli (S)

Institute of Genetics and Biophysics "Adriano Buzzati Traverso", National Research Council, Naples, Italy.

Paola Franco (P)

Institute of Genetics and Biophysics "Adriano Buzzati Traverso", National Research Council, Naples, Italy.

Marialucia Telesca (M)

Institute of Genetics and Biophysics "Adriano Buzzati Traverso", National Research Council, Naples, Italy.

Ingram Iaccarino (I)

Institute of Genetics and Biophysics "Adriano Buzzati Traverso", National Research Council, Naples, Italy.
Hematopathology Section, University Hospital Schleswig-Holstein Campus Kiel, Christian-Albrechts University, Kiel, Germany.

Gerardo Botti (G)

Pathology Unit, IRCCS National Cancer Institute "Fondazione G. Pascale", Naples, Italy.

Maria V Carriero (MV)

Department of Experimental Oncology, IRCCS National Cancer Institute "Fondazione G. Pascale", Naples, Italy.

Marie Ranson (M)

Illawarra Health and Medical Research Institute, Wollongong, NSW, Australia.
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW, Australia.

Maria Patrizia Stoppelli (MP)

Institute of Genetics and Biophysics "Adriano Buzzati Traverso", National Research Council, Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH